Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

CD44 in Group 1 Innate Lymphoid Cells Impacts the Development and Progression of Steatohepatitis

Bourinet M., Vieira E., Rousseau D., Bonnafous S., Soysouvanh F., Strazzulla A.

Animal Study on Chronic Inflammation, published in Liver Int (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Liver Int (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40851484
PMCID
PMC12375942
DOI
10.1111/liv.70299
Citations
2

Abstract (original English)

Background and aims Innate lymphoid cells (ILCs) play pivotal roles in inflammation and fibrosis, which are key features of chronic liver diseases. The contribution of group 1 ILCs, including natural killer (NK) cells and helper-like ILC1s, to liver inflammation during steatohepatitis and metabolic dysfunction-associated steatotic liver diseases (MASLD) is still a matter of debate and requires further investigation. Methods We engineered a mouse model of specific deficiency of CD44 in group 1 ILCs and challenged mice with diet-induced obesity and MASLD or diet-induced steatohepatitis. We performed in vitro studies and co-cultured LPS-stimulated liver NK cells with hepatocytes and macrophages to analyse the inflammatory response. Results As group 1 ILCs expressed the cell surface molecule CD44, its specific targeting was used to investigate if CD44 could affect the development of liver inflammation. Here, we found that CD44 deficiency in group 1 ILCs was sufficient to decrease the absolute number of hepatic NKp46 + ILCs, NK cells and ILC1s in chow diet and in response to diet induced-MASLD or steatohepatitis. CD44 deficiency in group 1 ILCs aggravated liver complications by exacerbating hepatic injury, inflammation, and fibrosis, which was also associated with inflammatory and osteopontin + macrophages accumulation. The absence of CD44 in NK cells enhanced their inflammatory phe

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
LiverLymphocytesKiller Cells, NaturalMacrophagesHepatocytesAnimalsMice, Inbred C57BLMiceFatty LiverObesity

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research